For a study, researchers sought to assess early-phase CT findings of ground-glass opacity (GGOp-LC) following stereotactic body radiation (SBRT). Patients with cTis-2bN0M0 GGOp-LC treated with SBRT were identified retrospectively. The CT scans were evaluated using radiologists’ interpretation and density histograms. Additionally, long-term therapy outcomes were evaluated. This study analyzed 126 individuals with 133 cases of GGOp-LC, including GGOp-LC with pure GGO (pureGGO-LC) (n=31) and part-solid tumors (partsolid-LC) (n=102). The median follow-up period was 64.3 months (range, 10.8-178.9 months). At 1 and 3 months following SBRT, the majority of GGOp-LC cases were regarded as stable illnesses (96% [125/130] and 85% [62/73], respectively). Nonetheless, the solid component was frequently viewed as a sign of increasing disease (42% [34/82] and 60% [29/48], respectively). In 47% (61/130) and 86% (63/73) of the cases, respectively, the GGO component was denser. The median tumor density values for 25 evaluable pureGGO-LC cases at 3 months increased over time (P<.001). The median regions of CT-density ≥ -160 HU increased over time for 48 evaluable partsolid-LC instances at 3 months (P<.001). The overall 5-year survival rate for GGOp-LC patients was 78.0%. There were no local or regional recurrences observed. The SBRT results for GGOp-LC were outstanding, with no local or regional recurrence. In the analysis of early-phase follow-up CT scans of GGOp-LC after SBRT, it should be observed that the majority of the illness remains stable, the solid component grows in size, and the GGO component becomes denser.
- Business of Medicine
- Doctor’s Voice